Drugs / EBV specific CTLs
EBV specific CTLs
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00706316 | Dec 2007 → Aug 2009 | nasopharyngeal carcinoma | University Health Network, Toronto | Completed | No outcome recorded |
| Phase 1 | NCT00085930 | Apr 2003 → Jan 2010 | neuroblastoma | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00058604 | Jan 2001 → Dec 2008 | Epstein-Barr virus infection, lymphoproliferative syndrome | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00058591 | Jan 2000 → Dec 2008 | Epstein-Barr virus infection | Baylor College of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT00058617 | Jan 1996 → Aug 2011 | Epstein-Barr virus-associated lymphoproliferative disorder, plasma cell neoplasm | Baylor College of Medicine | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EBV specific CTLs | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00058604 ↗ |
| Known as | CTLs | “uses Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes (CTLs).” NCT00058591 ↗ |
| Known as | EBV specific cytotoxic T lymphocytes | “uses Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes (CTLs).” NCT00058591 ↗ |
| Known as | EBV-CTLs | “Two distinguishable forms of this CAR were expressed in EBV-specific cytotoxic T lymphocytes (EBV-CTLs) and activated T cells (ATCs).” PMID 21984804 ↗ Oct 2011 |
| Known as | Epstein Barr virus specific cytotoxic T lymphocytes | “Patients are being asked to volunteer to be in a research study using Epstein Barr virus specific cytotoxic T lymphocytes, a new experimental therapy.” NCT00058617 ↗ |
| Action | Deplete | “trained to kill EBV infected cells” NCT00058591 ↗ |
| Modality | Cell therapy | “uses Epstein-Barr virus (EBV) specific cytotoxic T lymphocytes (CTLs).” NCT00058591 ↗ |
| Route | Intravenous | “the T cells will be injected into a vein over a 10 minute period” NCT00058591 ↗ |